Commercialization

Bonegrafix intends to develop products using its proprietary technology to produce unique, cost-effective bone replacement devices with regenerative autograft/allograft properties and no complications.  Bonegrafix patent estate includes drug, formulation and manufacturing patents that provide numerous options for internally derived products as well as partnering opportunities.

Bonegrafix’ corporate strategy is to commercialize and sell products under the Company label in North America and partner for sales in Europe and Asia.  The Company will proactively seek intellectual property complementary to its current pipeline and consistent with its corporate mission.